

1Additional file 5: Table S5: Cumulative risk effects of *IKZF1*, *ARID5B* and *CEBPE* genetic variants according to leukemia subtype and *MLL* status, Brazil, 2003-22013

	Controls		Overall cases		ALL				AML		<i>MLL</i> germline		<i>MLL-r</i>		
	n	n	OR (95% CI) ^b	≤12 months		13-24 months		n	OR (95% CI) ^b	n	OR (95% CI) ^b	n	OR (95% CI) ^b	n	OR (95% CI) ^b
				n	OR (95% CI) ^b	n	OR (95% CI) ^b								
Number of risk alleles ^a															
0-1	41	9	1.00	4	1.00	0	-	5	1.00	4	1.00	4	1.00		
2	68	27	1.94 (0.92-4.12)	13	2.06 (0.71-5.98)	5	1.00	9	1.09 (0.34-	10	1.50 (0.44-5.12)	14	2.13 (0.66-6.96)		
3	123	53	1.43 (0.98-2.06)	23	1.41 (0.83-2.39)	10	1.06 (0.61-1.86)	20	1.15 (0.68-1.95)	23	1.38 (0.79-2.42)	27	1.50 (0.86-2.62)		
4	101	52	1.34 (1.04-1.73)	15	1.17 (0.81-1.70)	17	1.32 (0.93-1.87)	20	1.17 (0.82-1.66)	23	1.33 (0.91-1.93)	24	1.35 (0.93-1.95)		
5	77	35	1.21 (0.99-1.48)	15	1.19 (0.90-1.59)	11	1.21 (0.91-1.60)	9	0.99 (0.74-1.33)	13	1.16 (0.86-1.56)	19	1.26 (0.95-1.68)		
6-8	59	43	1.27 (1.09-1.48)	11	1.17 (0.93-1.47)	19	1.34 (1.09-1.66)	13	1.12 (0.89-1.39)	24	1.33 (1.06-1.67)	17	1.25 (0.99-1.58)		

³ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; n, number of individuals; OR, odds ratio; CI, confidence intervals; ^aRefers to the cumulative number of variant

⁴alleles of *IKZF1*, *ARID5B* and *CEBPE* genes in the same patient; only patients analyzed for all four loci have been included in this analyses; ^bAdjusted on skin color.